Navigation Links
Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 'CONNECTION' Trial of Dimebon in Patients With Alzheimer's Disease
Date:6/11/2009

In September 2008, Medivation announced a global agreement with Pfizer Inc to develop and commercialize dimebon for the treatment of Alzheimer's and Huntington diseases. With Pfizer, the Company is conducting a broad dimebon clinical development program that includes several Phase 3 trials assessing the efficacy and safety of dimebon taken alone or in combination with other Alzheimer's medications in patients with mild, moderate or severe Alzheimer's disease. Further development of dimebon in patients with Huntington disease is also planned. In addition, a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer is ongoing, and a Phase 3 trial is expected to begin this year. For more information, please visit us at http://www.medivation.com.

This press release contains forward-looking statements, including statements regarding the timing and potential results of clinical trials, and the anticipated timing of regulatory filings, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Medivation's actual results to differ significantly from those projected, including, without limitation, risks related to progress, timing and results of Medivation's clinical trials, difficulties or delays in obtaining regulatory approval, enrollment of patients in Medivation's clinical trials, partnering of Medivation's product candidates, manufacturing of Medivation's product candidates, competition with Medivation's product candidates should they receive marketing approval, the adequacy of Medivation's financial reso
'/>"/>

SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Medivation Announces Pricing of Public Offering
2. Medivation Announces First Quarter 2009 Financial Results Teleconference and Webcast on May 11, 2009
3. Medivation Announces Upcoming Scientific Presentations at Medical Conferences
4. Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update
5. Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
6. Medivation Presents New Data on Dimebons Novel Mechanism of Action
7. Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference
8. Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
9. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
10. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
11. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... New York (PRWEB) August 22, 2014 ... one of the interesting and challenging endeavors as ... renders highly impervious properties to the foreign substances. ... as possibility of self medication and minimal use ... low molecular weight drugs and provides specific targeting ...
(Date:8/22/2014)... 2014 The AMA is pleased to ... in Alaska that Alaska Governor Sean Parnell has signed ... defining public use of Unmanned Aircraft Systems and the ... Bill 255states that it is, “An Act relating to ... an unmanned aircraft system.” It defines State of Alaska ...
(Date:8/21/2014)... Aug. 21, 2014  BioSpecifics Technologies Corp. (NASDAQ: ... first in class collagenase-based products marketed as XIAFLEX ... the U.S. and XIAPEX ® in the ... a randomized, double-blind Phase 2a study of CCH ... fibrosclerotic panniculopathy. The results showed that all three ...
(Date:8/21/2014)... 21, 2014 2014 Deep ... is a professional and in-depth research report ... provides basic Seaweed Fertilizer information, including Seaweed ... structure as well as industry overview. This ... domestic market as well as global industry ...
Breaking Biology Technology:Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4State of Alaska Signs Unmanned Aircraft Systems Bill 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 3
... ... -, SOUTH ... of a recent Harris,Interactive(R) survey, showing that an overwhelming majority of Tracleer,patients ... their knowledge of pulmonary arterial hypertension (PAH) and,Tracleer have improved due to ...
... /PRNewswire-FirstCall/ - Helix BioPharma Corp.,(TSX, FSE: "HBP") today announced financial results ... HIGHLIGHTS ---------- - Subsequent to the ... CDN$16.9 million private placement of common shares, subject to ... with Dr. Donald H. Segal remaining the ...
... 17 IRIDEX,Corporation (Nasdaq: IRIX ) today ... Company as Chief Financial Officer effective January 2, ... Officer and Vice President,of Finance for NextHop Technologies, ... as Vice President of Finance and Chief,Financial Officer ...
Cached Biology Technology:Survey of More than 600 Patients Treated with Tracleer(R) (bosentan) Reveals Actelion Sure Steps(R) Patient Support Program Provides Valuable Educational Information 2Survey of More than 600 Patients Treated with Tracleer(R) (bosentan) Reveals Actelion Sure Steps(R) Patient Support Program Provides Valuable Educational Information 3Survey of More than 600 Patients Treated with Tracleer(R) (bosentan) Reveals Actelion Sure Steps(R) Patient Support Program Provides Valuable Educational Information 4Helix BioPharma announces Q1 2008 financial results 2Helix BioPharma announces Q1 2008 financial results 3Helix BioPharma announces Q1 2008 financial results 4Helix BioPharma announces Q1 2008 financial results 5Helix BioPharma announces Q1 2008 financial results 6Helix BioPharma announces Q1 2008 financial results 7Helix BioPharma announces Q1 2008 financial results 8Helix BioPharma announces Q1 2008 financial results 9Helix BioPharma announces Q1 2008 financial results 10Helix BioPharma announces Q1 2008 financial results 11IRIDEX Announces James Mackaness Will Be Chief Financial Officer 2
(Date:8/21/2014)... to ignore, but they are the ultimate source of ... are increasingly dependent on algae, too, to suck up ... to the bottom of the ocean. Now, by using ... have evidence showing that viruses infecting those algae are ... when all else stays essentially the same, and this ...
(Date:8/21/2014)... MELBOURNE, Fla. , Aug. 21, 2014 ...  announced that it has agreed to a ... Orlando,s fastest growing Certified ... make  Gabriel Health Institute  an exclusive member ... a result, Binary Biometrics will improve its ...
(Date:8/21/2014)... from Beth Israel Deaconess Medical Center (BIDMC ) are ... Influential Scientific Minds 2014," a comprehensive list ... resource for science metrics and research performance analysis. ... influential "are performing and publishing work that their peers ... according to a Thomson Reuters statement. Researchers were identified ...
Breaking Biology News(10 mins):Viruses take down massive algal blooms, with big implications for climate 2LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 2LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 3BIDMC researchers named among 'the most influential scientific minds' 2BIDMC researchers named among 'the most influential scientific minds' 3
... spiders, and other venomous creatures, the "business end," or active ... of a protein that is most likely to undergo rapid ... Gurion University in Israel. Understanding these evolutionary forces can help ... and may also aid in the design of novel synthetic ...
... world, allocating limited health care resources as effectively and ... address that need, systems engineers at the Georgia Institute ... nations improve supply chain decisions related to the distribution ... are also forecasting what health care services would be ...
... Extensive ongoing research on biotic invasions around the world ... research in the United States shows how using improved ... plant species changes the understanding of patterns of species ... was published in the open access journal ...
Cached Biology News:Molding the business end of neurotoxins 2Engineers improve allocation of limited health care resources in resource-poor nations 2Engineers improve allocation of limited health care resources in resource-poor nations 3Human population the primary factor in exotic plant invasions in the United States 2
Request Info...
R26.4C...
... Specifications(L x W x H): 17 ... 5 5/16"18.7 lbsCapacity: 12 slidesTime: Programmable 0 ... Automated denaturation and hybridization steps 40 user ... only, and Fixed temperature) Rapid temperature ramp-up ...
Anti-DAP-1, Rabbit Monoclonal Immunogen: KLH-conjugated synthetic peptide corresponding to the C-terminal region of human DAP-1. Molecular Weight: 11 kDa Quality Assurance: Routinely eval...
Biology Products: